{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:34:13Z","timestamp":1787063653501,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejmech.2021.113437","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T21:05:49Z","timestamp":1618952749000},"page":"113437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment"],"prefix":"10.1016","volume":"220","author":[{"given":"Yu","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunqi","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengda","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113437_bib1","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1021\/acs.jmedchem.8b00173","article-title":"Factor XIa inhibitors as new anticoagulants","volume":"61","author":"Quan","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib2","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1021\/jm5010607","article-title":"Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in\u00a0vivo antithrombotic activity","volume":"57","author":"Hangeland","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.drudis.2014.04.018","article-title":"Inhibition of factor XI activity as a promising antithrombotic strategy","volume":"19","author":"Chen","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2021.113437_bib4","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1021\/acs.jmedchem.0c00464","article-title":"Discovery of a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species","volume":"63","author":"Yang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/13543776.2016.1154045","article-title":"Factor XIa inhibitors: a review of the patent literature","volume":"26","author":"Al-Horani","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.113437_bib6","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/med.21503","article-title":"Recent advances in the discovery and development of factor xi\/xia inhibitors","volume":"28","author":"Al-Horani","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113437_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-011-0599-0","article-title":"A\u00a0small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits","volume":"32","author":"Wong","year":"2011","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.ejmech.2021.113437_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejmech.2016.05.039","article-title":"Contemporary developments in the discovery of selective factor Xa inhibitors: a review","volume":"121","author":"Patel","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.109.197178","article-title":"Inhibition of factor XIa as a new approach to anticoagulation","volume":"30","author":"Schumacher","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2021.113437_bib10","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acsmedchemlett.5b00066","article-title":"Discovery of a potent parenterally administered factor XIa inhibitor with hydroxyquinolin-2(1H)-one as the P2\u2032 moiety","volume":"6","author":"Hu","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113437_bib11","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1021\/jm501045e","article-title":"Design, synthesis, and structure\u2013activity and structure\u2013pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor","volume":"57","author":"Xue","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib12","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2146\/ajhp150821","article-title":"Edoxaban: a direct oral anticoagulant","volume":"74","author":"Poulakos","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2021.113437_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ejmech.2016.12.015","article-title":"Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: design, synthesis and anticoagulant activity evaluation","volume":"126","author":"Yang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejmech.2018.01.067","article-title":"The selectivity and bioavailability improvement of novel oral anticoagulants: an overview","volume":"146","author":"Xie","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib16","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1021\/acs.jmedchem.0c00279","article-title":"Structure-based design and preclinical characterization of selective and orally bioavailable factor XIa inhibitors: demonstrating the power of an integrated S1 protease family approach","volume":"63","author":"Lorthiois","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1021\/acs.jmedchem.9b01768","article-title":"Potent, orally bioavailable, and efficacious macrocyclic inhibitors of factor XIa. Discovery of pyridine-based macrocycles possessing phenylazole carboxamide P1 groups","volume":"63","author":"Corte","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib18","doi-asserted-by":"crossref","first-page":"127072","DOI":"10.1016\/j.bmcl.2020.127072","article-title":"Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants","volume":"30","author":"Hussain","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113437_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11239-015-1258-7","article-title":"In\u00a0vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa","volume":"40","author":"Wong","year":"2015","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.ejmech.2021.113437_bib20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1021\/acs.jmedchem.6b01460","article-title":"Structure-based design of macrocyclic factor XIa inhibitors: discovery of the macrocyclic amide linker","volume":"60","author":"Corte","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib21","doi-asserted-by":"crossref","first-page":"9703","DOI":"10.1021\/acs.jmedchem.7b01171","article-title":"Discovery of a parenteral small molecule coagulation factor XIa inhibitor clinical candidate (BMS-962212)","volume":"60","author":"Pinto","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2010","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2021.113437_bib23","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113437_bib24","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A\u00a0role for factor XIIa\u2013mediated factor XI activation in thrombus formation in\u00a0vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113437_bib25","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868\u2014a novel FXI antibody with a unique binding mode\u2014shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113437_bib26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17460441.2017.1384811","article-title":"Discovery methods of coagulation-inhibiting drugs","volume":"12","author":"G\u00f3mez-Outes","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113437_bib27","article-title":"EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: a brief report","volume":"2","author":"Pollack","year":"2020","journal-title":"Crit. Care Explor."},{"key":"10.1016\/j.ejmech.2021.113437_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14728214.2019.1591368","article-title":"Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation","volume":"24","author":"Sz\u00e9kely","year":"2019","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2021.113437_bib29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/jm401670x","article-title":"Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors","volume":"57","author":"Quan","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib30","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bmcl.2015.11.089","article-title":"Novel phenylalanine derived diamides as factor XIa inhibitors","volume":"26","author":"Smith","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113437_bib31","doi-asserted-by":"crossref","first-page":"15752","DOI":"10.1021\/acs.jmedchem.0c01524","article-title":"Switching a xanthine oxidase inhibitor to a dual-target antagonist of P2Y1 and P2Y12 as an oral antiplatelet agent with a wider therapeutic window in rats than ticagrelor","volume":"63","author":"Lei","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejmech.2015.08.056","article-title":"Synthesis and evaluation of 1-hydroxy\/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors","volume":"103","author":"Chen","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jchromb.2019.03.013","article-title":"A\u00a0novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC\u2013MS\/MS","volume":"1113","author":"Zhang","year":"2019","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.ejmech.2021.113437_bib34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd1467","article-title":"Fragment-based lead discovery","volume":"3","author":"Rees","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113437_bib35","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.ddtec.2010.11.003","article-title":"Ligand efficiency as a guide in fragment hit selection and optimization","volume":"7","author":"Schultes","year":"2010","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2021.113437_bib36","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113437_bib37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/1087057109336751","article-title":"Mechanism-based inhibition: deriving ki and kinact directly from time-dependent ic50 values","volume":"14","author":"Krippendorff","year":"2010","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.ejmech.2021.113437_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-016-0249-9","article-title":"New approaches for the reliable in\u00a0vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics","volume":"7","author":"Zeilinger","year":"2017","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2021.113437_bib39","unstructured":"Glide, Schrodinger, LLC, New York, NY, 2016."},{"key":"10.1016\/j.ejmech.2021.113437_bib40","doi-asserted-by":"crossref","first-page":"11145","DOI":"10.1039\/c3cp00054k","article-title":"Halogen bonding and other \u03c3-hole interactions: a perspective","volume":"15","author":"Politzer","year":"2013","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejmech.2021.113437_bib41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11239-015-1258-7","article-title":"In\u00a0vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa","volume":"40","author":"Wong","year":"2015","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.ejmech.2021.113437_bib42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/em.21997","article-title":"Peptide bond-forming reagents HOAt and HATU are not mutagenic in the bacterial reverse mutation test","volume":"57","author":"Nicolette","year":"2016","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.ejmech.2021.113437_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/molecules23082002","article-title":"Fragment-based lead generation of 5-phenyl-1H-pyrazole-3-carboxamide derivatives as leads for potent factor Xia inhibitors","volume":"23","author":"Wei","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113437_bib44","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1016\/j.bmc.2006.08.010","article-title":"Potent and selective TF\/FVIIa inhibitors containing a neutral P1 ligand","volume":"14","author":"Miura","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib45","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1021\/acs.jmedchem.7b01625","article-title":"Stable and long-lasting, novel bicyclic peptide plasma kallikrein inhibitors for the treatment of diabetic macular edema","volume":"61","author":"Teufel","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib46","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.bmc.2017.03.055","article-title":"Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity","volume":"25","author":"Sun","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113437_bib47","series-title":"Version 4. 5","author":"Visualizer","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113437_bib48","unstructured":"The PyMOL Molecular Graphics System, version 1.5.0.3; Schr\u00f6dinger, LLC: New York."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:25:10Z","timestamp":1759328710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421002865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":48,"alternative-id":["S0223523421002865"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113437","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113437"}}